J 2005

The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

POHANKA, Michal, Petr KAŇOVSKÝ, Martin BAREŠ, Jiří PULKRÁBEK, Ivan REKTOR et. al.

Basic information

Original name

The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up

Name in Czech

Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování

Authors

POHANKA, Michal (203 Czech Republic), Petr KAŇOVSKÝ (203 Czech Republic, guarantor), Martin BAREŠ (203 Czech Republic), Jiří PULKRÁBEK (203 Czech Republic) and Ivan REKTOR (203 Czech Republic)

Edition

Česká a slovenská neurologie a neurochirurgie, Česká lékařská společnost J.E.Purkyně, 2005, 1210-7859

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.070

RIV identification code

RIV/00216224:14110/05:00031906

Organization unit

Faculty of Medicine

UT WoS

000233791000006

Keywords in English

Pergolid; Parkinson disease; treatment; sexual dysfunction

Tags

International impact, Reviewed
Změněno: 31/3/2010 23:31, prof. MUDr. Martin Bareš, Ph.D.

Abstract

V originále

The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.

In Czech

Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování

Links

MSM0021622404, plan (intention)
Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.